Skip to Content
Merck
CN
  • Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.

Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.

Molecular cell (2021-07-04)
Jaclyn M Einstein, Mark Perelis, Isaac A Chaim, Jitendra K Meena, Julia K Nussbacher, Alexandra T Tankka, Brian A Yee, Heyuan Li, Assael A Madrigal, Nicholas J Neill, Archana Shankar, Siddhartha Tyagi, Thomas F Westbrook, Gene W Yeo
ABSTRACT

RNA-binding proteins (RBPs) are critical regulators of post-transcriptional gene expression, and aberrant RBP-RNA interactions can promote cancer progression. Here, we interrogate the function of RBPs in cancer using pooled CRISPR-Cas9 screening and identify 57 RBP candidates with distinct roles in supporting MYC-driven oncogenic pathways. We find that disrupting YTHDF2-dependent mRNA degradation triggers apoptosis in triple-negative breast cancer (TNBC) cells and tumors. eCLIP and m6A sequencing reveal that YTHDF2 interacts with mRNAs encoding proteins in the MAPK pathway that, when stabilized, induce epithelial-to-mesenchymal transition and increase global translation rates. scRibo-STAMP profiling of translating mRNAs reveals unique alterations in the translatome of single cells within YTHDF2-depleted solid tumors, which selectively contribute to endoplasmic reticulum stress-induced apoptosis in TNBC cells. Thus, our work highlights the therapeutic potential of RBPs by uncovering a critical role for YTHDF2 in counteracting the global increase of mRNA synthesis in MYC-driven breast cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4-Phenylbutyric acid, 99%
Sigma-Aldrich
(Z)-4-Hydroxytamoxifen, ≥98% Z isomer
Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Poly-D-lysine hydrobromide, mol wt 70,000-150,000, lyophilized powder, γ-irradiated, BioReagent, suitable for cell culture
Sigma-Aldrich
Anti-Puromycin Antibody, clone 12D10, clone 12D10, from mouse